Quarterly ResultMay 12, 2026, 07:07 AM
Opus Genetics Q1 Net Loss $65.5M; Cash Runway into 2029; Pipeline Advances
AI Summary
Opus Genetics reported a net loss of $65.5 million for the first quarter ended March 31, 2026, a significant increase from $8.2 million in the prior year, primarily due to a non-cash expense from warrant liabilities. Despite this, the company announced a strong cash position of approximately $90 million, including recent financing, which is expected to fund operations into 2029. The company also provided positive corporate updates, including encouraging momentum in its OPGx-LCA5 and OPGx-BEST1 gene therapy programs, with key data readouts and clinical advancements anticipated.
Key Highlights
- Net loss for Q1 2026 was $65.5 million, compared to $8.2 million in Q1 2025.
- Net loss per share was ($0.75) for Q1 2026, versus ($0.24) in Q1 2025.
- Cash and cash equivalents totaled $60 million as of March 31, 2026.
- Secured $35 million in senior notes and $5 million equity investment, extending cash runway into 2029.
- License and collaborations revenue decreased to $2.2 million from $4.4 million year-over-year.
- OPGx-LCA5 showed positive six-month pediatric data and was accepted into FDA's RDEP program.
- OPGx-BEST1 Cohort 1 topline data is expected in September 2026.
- OPGx-RDH12 and OPGx-RHO programs are expected to enter the clinic in Q4 2026 and 2027, respectively.